106190 — High Tech Pharm Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩181bn
- KR₩183bn
- KR₩77bn
- 55
- 39
- 65
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 63,068 | 74,462 | 73,287 | 102,947 | 76,772 |
Cost of Revenue | |||||
Gross Profit | -2,116 | 1,314 | 3,078 | 7,779 | 12,843 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 67,593 | 77,819 | 73,699 | 98,020 | 66,683 |
Operating Profit | -4,525 | -3,357 | -412 | 4,927 | 10,089 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3,905 | -2,600 | -868 | 4,028 | 9,864 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4,218 | -3,152 | -1,225 | 5,873 | 8,076 |
Net Income Before Extraordinary Items | |||||
Net Income | -4,218 | -3,152 | -1,225 | 5,873 | 8,076 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -4,218 | -3,152 | -1,225 | 5,873 | 8,076 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -397 | -294 | -115 | 544 | 755 |
Dividends per Share |